BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26581548)

  • 1. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.
    Catenacci DVT; Liao WL; Zhao L; Whitcomb E; Henderson L; O'Day E; Xu P; Thyparambil S; Krizman D; Bengali K; Uzzell J; Darfler M; Cecchi F; Blackler A; Bang YJ; Hart J; Xiao SY; Lee SM; Burrows J; Hembrough T
    Gastric Cancer; 2016 Oct; 19(4):1066-1079. PubMed ID: 26581548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.
    Catenacci DV; Liao WL; Thyparambil S; Henderson L; Xu P; Zhao L; Rambo B; Hart J; Xiao SY; Bengali K; Uzzell J; Darfler M; Krizman DB; Cecchi F; Bottaro DP; Karrison T; Veenstra TD; Hembrough T; Burrows J
    PLoS One; 2014; 9(7):e100586. PubMed ID: 24983965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
    Catenacci DV; Ang A; Liao WL; Shen J; O'Day E; Loberg RD; Cecchi F; Hembrough T; Ruzzo A; Graziano F
    Cancer; 2017 May; 123(6):1061-1070. PubMed ID: 27926778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
    Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
    Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
    Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
    J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization.
    Radu OM; Foxwell T; Cieply K; Navina S; Dacic S; Nason KS; Davison JM
    Am J Clin Pathol; 2012 Apr; 137(4):583-94. PubMed ID: 22431535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer.
    Ahn S; Hong M; Van Vrancken M; Lyou YJ; Kim ST; Park SH; Kang WK; Park YS; Jung SH; Woo M; Lee J; Kim KM
    Mol Diagn Ther; 2016 Aug; 20(4):375-83. PubMed ID: 27179810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification.
    Abdelhakeem A; Wang X; Rogers JE; Trail A; Zhao M; Blum-Murphy M; Estrella JS; Ajani JA
    Oncology; 2020; 98(12):884-888. PubMed ID: 32998149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.
    Nuciforo P; Thyparambil S; Aura C; Garrido-Castro A; Vilaro M; Peg V; Jimenez J; Vicario R; Cecchi F; Hoos W; Burrows J; Hembrough T; Ferreres JC; Perez-Garcia J; Arribas J; Cortes J; Scaltriti M
    Mol Oncol; 2016 Jan; 10(1):138-147. PubMed ID: 26422389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
    Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
    Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
    Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
    Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification.
    Xu B; Chen H; Zhang J; Cong Y; Ning L; Chen L; Zhang Y; Zhang Y; Song Z; Meng Y; He L; Liao WL; Lu Y; Zhao F
    Front Oncol; 2023; 13():1152895. PubMed ID: 37350943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
    Grin A; Brezden-Masley C; Bauer S; Streutker CJ
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
    Yoon HH; Sukov WR; Shi Q; Sattler CA; Wiktor AE; Diasio RB; Wu TT; Jenkins RB; Sinicrope FA
    Cancer; 2014 Feb; 120(3):415-24. PubMed ID: 24151090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.